Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Xeris Pharmaceuticals Inc is a biotechnology business based in the US. Xeris Pharmaceuticals shares (XERS) are listed on the NASDAQ and all prices are listed in US Dollars. Xeris Pharmaceuticals employs 253 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.95|
|52-week range||$1.95 - $7.94|
|50-day moving average||$2.46|
|200-day moving average||$3.26|
|Wall St. target price||$8.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-1.47|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-14)||-2.99%|
|1 month (2021-09-21)||-19.75%|
|3 months (2021-07-21)||-46.28%|
|6 months (2021-04-21)||-49.74%|
|1 year (2020-10-21)||-63.00%|
|2 years (2019-10-21)||-77.25%|
|3 years (2018-10-19)||19.94|
|5 years (2016-10-17)||N/A|
|Revenue TTM||$33.7 million|
|Gross profit TTM||$11.2 million|
|Return on assets TTM||-27.47%|
|Return on equity TTM||-378.52%|
|Market capitalisation||$250.7 million|
TTM: trailing 12 months
There are currently 4.1 million Xeris Pharmaceuticals shares held short by investors – that's known as Xeris Pharmaceuticals's "short interest". This figure is 5.1% down from 4.3 million last month.
There are a few different ways that this level of interest in shorting Xeris Pharmaceuticals shares can be evaluated.
Xeris Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Xeris Pharmaceuticals shares currently shorted divided by the average quantity of Xeris Pharmaceuticals shares traded daily (recently around 1.0 million). Xeris Pharmaceuticals's SIR currently stands at 3.93. In other words for every 100,000 Xeris Pharmaceuticals shares traded daily on the market, roughly 3930 shares are currently held short.
However Xeris Pharmaceuticals's short interest can also be evaluated against the total number of Xeris Pharmaceuticals shares, or, against the total number of tradable Xeris Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Xeris Pharmaceuticals's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 Xeris Pharmaceuticals shares in existence, roughly 60 shares are currently held short) or 0.0647% of the tradable shares (for every 100,000 tradable Xeris Pharmaceuticals shares, roughly 65 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Xeris Pharmaceuticals.
Find out more about how you can short Xeris Pharmaceuticals stock.
We're not expecting Xeris Pharmaceuticals to pay a dividend over the next 12 months.
Xeris Pharmaceuticals's shares were split on 5 October 2021.
Over the last 12 months, Xeris Pharmaceuticals's shares have ranged in value from as little as $1.95 up to $7.94. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xeris Pharmaceuticals's is 1.8103. This would suggest that Xeris Pharmaceuticals's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Xeris Biopharma Holdings, Inc. , a biopharmaceutical company, engages in developing and commercializing therapies for patient populations in endocrinology, neurology, and gastroenterology. It markets Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a therapy for primary periodic paralysis. The company also has a pipeline of development programs to extend the marketed products into new indications and uses and bring new products using its proprietary formulation technology platforms, XeriSol and XeriJect. The company was founded in 2005 and is headquartered in Chicago, Illinois. .
Everything we know about the Aura Biosciences IPO, plus information on how to buy in.
Everything we know about the Claros Mortgage Trust IPO, plus information on how to buy in.
Everything we know about the Evotec SE IPO, plus information on how to buy in.
Everything we know about the Delimobil Holding SA IPO, plus information on how to buy in.
Everything we know about the Blue Water Vaccines IPO, plus information on how to buy in.
Everything we know about the Sonendo IPO, plus information on how to buy in.
Everything we know about the FlexEnergy Green Solutions IPO, plus information on how to buy in.
Everything we know about the Stran & Company IPO, plus information on how to buy in.
Everything we know about the Kidpik Corp IPO, plus information on how to buy in.
Everything we know about the Nuvectis Pharma IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.